The DOI matches its Crossref record; 404 of the 409 references it cites were found in a registry or an index.
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
Abstract
G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiological functions of the catecholaminergic neurotransmitter dopamine, ranging from voluntary movement and reward to hormonal regulation and hypertension. Pharmacological agents targeting dopaminergic neurotransmission have been clinically used in the management of several neurological and psychiatric disorders, including Parkinson's disease, schizophrenia, bipolar disorder, Huntington's disease, attention deficit hyperactivity disorder (ADHD(1)), and Tourette's syndrome. Numerous advances have occurred in understanding the general structural, biochemical, and functional properties of dopamine receptors that have led to the development of multiple pharmacologically active compounds that directly target dopamine receptors, such as antiparkinson drugs and antipsychotics. Recent progress in understanding the complex biology of dopamine receptor-related signal transduction mechanisms has revealed that, in addition to their primary action on cAMP-mediated signaling, dopamine receptors can act through diverse signaling mechanisms that involve alternative G protein coupling or through G protein-independent mechanisms via interactions with ion channels or proteins that are characteristically implicated in receptor desensitization, such as β-arrestins. One of the future directions in managing dopamine-related pathologic conditions may involve a transition from the approaches that directly affect receptor function to a precise targeting of postreceptor intracellular signaling modalities either directly or through ligand-biased signaling pharmacology. In this comprehensive review, we discuss dopamine receptor classification, their basic structural and genetic organization, their distribution and functions in the brain and the periphery, and their regulation and signal transduction mechanisms. In addition, we discuss the abnormalities of dopamine receptor expression, function, and signaling that are documented in human disorders and the current pharmacology and emerging trends in the development of novel therapeutic agents that act at dopamine receptors and/or on related signaling events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with five dopamine receptors (D1-5), three norepinephrine receptors each with three subtypes (α1a,b,d, α2a,b,c and β1,2,3) and seven serotonin receptor families (5-HT1-7) comprised of 14 total receptors all of which are G-protein coupled, except for 5-HT3”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Beaulieu & Gainetdinov, 2011
Citations
Cites
Items 401–404 of 404
Beaulieu, J., Zhang, X., Rodriguiz, R. M., Sotnikova, T. D., Wetsel, W. C., Gainetdinov, R. R., & Caron, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803026105 · Cited by 6
Self-citationDopamine receptors oppositely regulate cocaine-induced transcription factor CREB activation.
Ny, L., Zhang, L., Wang, X.-N., & Zhang, L. (2006) · PubMed · Cited by 3
Axelrod, R. (1997) · PubMed · Cited by 1
beta -Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking
Kohout, T. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041608198
Flagged first, then by citations
5 of the 409 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Natural neural projection dynamics underlying social behavior
Gunaydin, L. A., Grosenick, L., Finkelstein, J. C., Kauvar, I. V., Fenno, L. E., Adhikari, A., Lammel, S., Mirzabekov, J. J., Airan, R. D., Zalocusky, K. A., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.017 · Cited by 1,389
Dopamine: Functions, Signaling, and Association with Neurological Diseases
Klein, M. O., Battagello, D. S., Cardoso, A. R., Hauser, D. N., Bittencourt, J. C., & Correa, R. G. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0632-3 · Cited by 1,073
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome
Yan, Y., Jiang, W., Liu, L., Wang, X., Ding, C., Tian, Z., & Zhou, R. (2015) · Cell · doi:10.1016/j.cell.2014.11.047 · Cited by 1,014
Sun, F., Zeng, J., Jing, M., Zhou, J., Feng, J., Owen, S. F., Luo, Y., Li, F., Wang, H., Yamaguchi, T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.042 · Cited by 837
Metadata
- Authors
- Beaulieu, J.-M., & Gainetdinov, R. R.
- Affiliations
- Université Laval (CA)
- Italian Institute of Technology (IT)
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2011-03
- Volume
- 63
- Issue
- 1
- Pages
- 182-217
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2097744565
- Cited by
- 2,763
- References
- 409
- Citations by year
- 2026: 157 · 2025: 183 · 2024: 172 · 2023: 193 · 2022: 201 · 2021: 197 · 2020: 198 · 2019: 220 · 2018: 200 · 2017: 187 · 2016: 205 · 2015: 175 · 2014: 194 · 2013: 136 · 2012: 101
- FWCI
- 13.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacological Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (NSA93798)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- dopamine receptors, dopamine D1/D5 receptors, G protein-coupled receptors, signal transduction, cAMP signaling, G protein-independent signaling, beta-arrestin, receptor desensitization, antiparkinsonian drugs, antipsychotic drugs
- MeSH terms
- Animals, Gene Expression Regulation, Humans, Ligands, Receptors, Dopamine, Signal Transduction, Dopamine Agonists, Dopamine Antagonists, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review